Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...

Background: Idiopathic Pulmonary fibrosis (IPF) is a complex and deadly disease with limited treatment options. A better understanding of the cellular and molecular mechanisms involved in IPF could ...

Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis. A new systematic review and meta-analysis suggests ...

Pulmonary haemorrhage (PH) after hybrid ventricular septal defect (VSD) closure has not been documented in the literature and is rarely reported after pulmonary artery debanding. We presented a ...

For Oneza Gite, life had quietly been getting harder over the past eight months. She was losing weight without trying. There were repeated episodes of heavy menstrual bleeding. And slowly, her energy ...

BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm ...

Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients with IPF BOSTON, March 25, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc., ...

Gear-obsessed editors choose every product we review. We may earn commission if you buy from a link. Why Trust Us? Here’s what you’ll learn when you read this story. Researchers who studied data from ...